213 related articles for article (PubMed ID: 33202000)
1. A proteomic glimpse into the effect of antimalarial drugs on Plasmodium falciparum proteome towards highlighting possible therapeutic targets.
Dousti M; Manzano-Román R; Rashidi S; Barzegar G; Ahmadpour NB; Mohammadi A; Hatam G
Pathog Dis; 2021 Jan; 79(1):. PubMed ID: 33202000
[TBL] [Abstract][Full Text] [Related]
2. A chemical proteomics approach for the search of pharmacological targets of the antimalarial clinical candidate albitiazolium in Plasmodium falciparum using photocrosslinking and click chemistry.
Penarete-Vargas DM; Boisson A; Urbach S; Chantelauze H; Peyrottes S; Fraisse L; Vial HJ
PLoS One; 2014; 9(12):e113918. PubMed ID: 25470252
[TBL] [Abstract][Full Text] [Related]
3. The use of proteomics for the identification of promising vaccine and diagnostic biomarkers in
Mansouri R; Ali-Hassanzadeh M; Shafiei R; Savardashtaki A; Karimazar M; Anvari E; Nguewa P; Rashidi S
Parasitology; 2020 Oct; 147(12):1255-1262. PubMed ID: 32618524
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development.
Deniskin R; Frame IJ; Sosa Y; Akabas MH
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):1-11. PubMed ID: 26862473
[TBL] [Abstract][Full Text] [Related]
5. Dramatic Consequences of Reducing Erythrocyte Membrane Cholesterol on Plasmodium falciparum.
Ahiya AI; Bhatnagar S; Morrisey JM; Beck JR; Vaidya AB
Microbiol Spectr; 2022 Feb; 10(1):e0015822. PubMed ID: 35196803
[TBL] [Abstract][Full Text] [Related]
6. Plasmodium falciparum proteome changes in response to doxycycline treatment.
Briolant S; Almeras L; Belghazi M; Boucomont-Chapeaublanc E; Wurtz N; Fontaine A; Granjeaud S; Fusaï T; Rogier C; Pradines B
Malar J; 2010 May; 9():141. PubMed ID: 20500856
[TBL] [Abstract][Full Text] [Related]
7. Antimalarial drugs and drug targets specific to fatty acid metabolic pathway of Plasmodium falciparum.
Qidwai T; Khan F
Chem Biol Drug Des; 2012 Aug; 80(2):155-72. PubMed ID: 22487082
[TBL] [Abstract][Full Text] [Related]
8. Cellular thermal shift assay for the identification of drug-target interactions in the Plasmodium falciparum proteome.
Dziekan JM; Wirjanata G; Dai L; Go KD; Yu H; Lim YT; Chen L; Wang LC; Puspita B; Prabhu N; Sobota RM; Nordlund P; Bozdech Z
Nat Protoc; 2020 Jun; 15(6):1881-1921. PubMed ID: 32341577
[TBL] [Abstract][Full Text] [Related]
9. [Transport proteins as drug targets in Plasmodium falciparum. New perspectives in the treatment of malaria].
Ellekvist P; Colding H
Ugeskr Laeger; 2006 Mar; 168(13):1314-7. PubMed ID: 16579884
[TBL] [Abstract][Full Text] [Related]
10. Identification via a Parallel Hit Progression Strategy of Improved Small Molecule Inhibitors of the Malaria Purine Uptake Transporter that Inhibit
Sosa Y; Deniskin R; Frame IJ; Steiginga MS; Bandyopadhyay D; Graybill TL; Kallal LA; Ouellette MT; Pope AJ; Widdowson KL; Young RJ; Akabas MH
ACS Infect Dis; 2019 Oct; 5(10):1738-1753. PubMed ID: 31373203
[TBL] [Abstract][Full Text] [Related]
11. In silico multiple-targets identification for heme detoxification in the human malaria parasite Plasmodium falciparum.
Phaiphinit S; Pattaradilokrat S; Lursinsap C; Plaimas K
Infect Genet Evol; 2016 Jan; 37():237-44. PubMed ID: 26626103
[TBL] [Abstract][Full Text] [Related]
12. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.
Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329
[TBL] [Abstract][Full Text] [Related]
13. Targeted repression of
Chakrabarti M; Garg S; Rajagopal A; Pati S; Singh S
Dis Model Mech; 2020 Jun; 13(6):. PubMed ID: 32493727
[TBL] [Abstract][Full Text] [Related]
14. Plasmodium falciparum Resistance to a Lead Benzoxaborole Due to Blocked Compound Activation and Altered Ubiquitination or Sumoylation.
Sindhe KMV; Wu W; Legac J; Zhang YK; Easom EE; Cooper RA; Plattner JJ; Freund YR; DeRisi JL; Rosenthal PJ
mBio; 2020 Jan; 11(1):. PubMed ID: 31992618
[TBL] [Abstract][Full Text] [Related]
15. Advances in omics-based methods to identify novel targets for malaria and other parasitic protozoan infections.
Cowell AN; Winzeler EA
Genome Med; 2019 Oct; 11(1):63. PubMed ID: 31640748
[TBL] [Abstract][Full Text] [Related]
16. Identification of Antimalarial Compounds That Require CLAG3 for Their Uptake by
Mira-Martínez S; Pickford AK; Rovira-Graells N; Guetens P; Tintó-Font E; Cortés A; Rosanas-Urgell A
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782998
[TBL] [Abstract][Full Text] [Related]
17. Antimalarial drug targets and drugs targeting dolichol metabolic pathway of Plasmodium falciparum.
Qidwai T; Priya A; Khan NA; Tripathi H; Khan F; Darokar MP; Pal A; Bawankule DU; Shukla RK; Bhakuni RS
Curr Drug Targets; 2014 Apr; 15(4):374-409. PubMed ID: 23848395
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis of Plasmodium falciparum schizonts reveals heparin-binding merozoite proteins.
Zhang Y; Jiang N; Lu H; Hou N; Piao X; Cai P; Yin J; Wahlgren M; Chen Q
J Proteome Res; 2013 May; 12(5):2185-93. PubMed ID: 23566259
[TBL] [Abstract][Full Text] [Related]
19. Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-malarial activity and their possible targets.
Mogire RM; Akala HM; Macharia RW; Juma DW; Cheruiyot AC; Andagalu B; Brown ML; El-Shemy HA; Nyanjom SG
PLoS One; 2017; 12(10):e0186364. PubMed ID: 29088219
[TBL] [Abstract][Full Text] [Related]
20. Effects of cyclin-dependent kinase inhibitor Purvalanol B application on protein expression and developmental progression in intra-erythrocytic Plasmodium falciparum parasites.
Bullard KM; Broccardo C; Keenan SM
Malar J; 2015 Apr; 14():147. PubMed ID: 25879664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
